Brigatinib
- Generic Name
- Brigatinib
- Brand Names
- Alunbrig
- Drug Type
- Small Molecule
- Chemical Formula
- C29H39ClN7O2P
- CAS Number
- 1197953-54-0
- Unique Ingredient Identifier
- HYW8DB273J
- Background
Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the EML4-ALK fusion gene, which is a pivotal ...
- Indication
The anaplastic lymphoma kinase positive, metastatic non-small cell lung cancer (ALK+ NSCLC), represents only 3-5% of the NSCLC cancer cases, but the ALK mutation, overexpression and presence in several oncogenic fusion proteins in solid and hematologic tumors have pointed out the importance as well as its potential as a cancer therapy target. The ALK-related...
- Associated Conditions
- Metastatic Non-Small Cell Lung Cancer
- Associated Therapies
- -
ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-08-01
- Last Posted Date
- 2024-08-09
- Target Recruit Count
- 80
- Registration Number
- NCT06532149
- Locations
- 🇮🇹
Fondazione Policlinico Gemelli IRCCS, Rome, Italy
Brigatinib Plus Chemotherapy or Local Consolidation Therapy in ALK Positive Advanced Non-small Cell Lung Cancer (BrightStar-2)
- Conditions
- Interventions
- First Posted Date
- 2024-07-26
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 168
- Registration Number
- NCT06522360
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
A Study to Compare the Relative Bioavailability of Brigatinib When Swallowed as a Solution Versus When Swallowed as a Tablet in Healthy Adults
- First Posted Date
- 2023-11-15
- Last Posted Date
- 2024-02-26
- Lead Sponsor
- Takeda
- Target Recruit Count
- 12
- Registration Number
- NCT06132867
- Locations
- 🇺🇸
Celerion, Inc., Tempe, Arizona, United States
A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.
- Conditions
- Interventions
- First Posted Date
- 2023-04-28
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 20605
- Registration Number
- NCT05834348
- Locations
- 🇳🇴
Pfizer Norway, Oslo, Norway
A Study to Learn About Brigatinib Treatment Information Available in Chinese Participants With Non-Small-cell Lung Cancer (NSCLC)
- First Posted Date
- 2023-02-10
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Takeda
- Target Recruit Count
- 200
- Registration Number
- NCT05721950
- Locations
- 🇨🇳
Department of Oncology, Shanghai pulmonary hospital, Shanghai, Shanghai, China
Brigatinib Post Definitive Chemo-radiotherapy in Patients with ALK-fusion Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-02-08
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 44
- Registration Number
- NCT05718297
- Locations
- 🇫🇷
CHU Angers, Angers, France
🇫🇷Caen - CHU, Caen, France
🇫🇷Hôpital de Marseille, Marseille, France
A Window of Opportunity Study for Investigating Drug Tolerant Persister (DTP) to Preoperative Brigatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Fusions.
- First Posted Date
- 2022-05-04
- Last Posted Date
- 2022-05-04
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 12
- Registration Number
- NCT05361564
- Locations
- 🇰🇷
Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of
Survey of Brigatinib Used To Treat People With Non-Small Cell Lung Cancer
- First Posted Date
- 2021-10-29
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- Takeda
- Target Recruit Count
- 500
- Registration Number
- NCT05100069
- Locations
- 🇯🇵
Takeda Selected Site, Tokyo, Japan
Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2021-06-14
- Last Posted Date
- 2022-09-28
- Lead Sponsor
- Princess Maxima Center for Pediatric Oncology
- Target Recruit Count
- 65
- Registration Number
- NCT04925609
- Locations
- 🇳🇱
Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands
🇫🇷Institut Gustave Roussy, Paris, France
Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.
- Conditions
- Interventions
- First Posted Date
- 2020-11-30
- Last Posted Date
- 2023-04-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 549
- Registration Number
- NCT04647110
- Locations
- 🇸🇪
Pfizer Innovations AB, Sollentuna, Sweden
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.